Head and Neck Medical Oncology Program
The UCSF Head and Neck Medical Oncology Program provides comprehensive world-class care for people with head and neck cancer. We evaluate and treat more than 600 patients every year. Our expertise covers the full range of treatments, from conventional chemotherapy and radiation to cutting-edge approaches, such as targeted therapies, which attack cancer cells without harming healthy cells, and immunotherapies, which recruit the patient's immune system to fight the cancer.
To determine the best treatment for an individual, our doctors work closely with colleagues from related specialties, including radiation oncology, otolaryngology – head and neck surgery, endocrinology, dental oncology and nutrition therapy. Partnering with many types of experts is essential to giving our patients the best possible outcomes, in both their cancer prognosis and their long-term quality of life.
We're also committed to developing new and better treatments for head and neck cancers through medical research. Interested patients may have the opportunity to take part in a clinical trial, a study of a promising experimental therapy. For information, visit UCSF's clinical trials website.
Learn more about clinical trials and how they work.
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients Wit...
For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.
Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Frequency and severity of Treatment Emergent Adverse Events (TEAEs) will be evaluated according to the NCI-CTCAE version 5.0 and number of participants with Dose Limiting Toxicities will be assessed to determine Safety and Tolerab...
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or M...
Treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Posi...
Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surger...
The proportion of patients experiencing grade 3 or 4 adverse events assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported with exact binomial 95% confidence intervals. Sa...
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma ...
TEAE's are defined as Adverse Events (AEs) with onset after date-time of first dose, or medical conditions present prior to the start of IMP but increased in severity or relationship after date-time of first dose of IMP.
Awards & recognition
One of the nation's best for ear, nose & throat care
Among the top hospitals in the nation
Best in Northern California and No. 7 in the nation for cancer care
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes